Harvard Bioscience, Inc. (HBIO): Price and Financial Metrics


Harvard Bioscience, Inc. (HBIO)

Today's Latest Price: $2.85 USD

0.09 (3.26%)

Updated Jun 5 4:00pm

Add HBIO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

HBIO Stock Summary

  • With a year-over-year growth in debt of -12.48%, Harvard Bioscience Inc's debt growth rate surpasses just 18.47% of about US stocks.
  • Over the past twelve months, HBIO has reported earnings growth of -403.17%, putting it ahead of only 4.24% of US stocks in our set.
  • The volatility of Harvard Bioscience Inc's share price is greater than that of merely 19.22% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to HBIO, based on their financial statements, market capitalization, and price volatility, are BDC, CAMP, VAPO, STIM, and LNDC.
  • Visit HBIO's SEC page to see the company's official filings. To visit the company's web site, go to www.harvardbioscience.com.
HBIO Daily Price Range
HBIO 52-Week Price Range

HBIO Stock Price Chart More Charts


HBIO Price/Volume Stats

Current price $2.85 52-week high $3.50
Prev. close $2.76 52-week low $1.39
Day low $2.79 Volume 132,190
Day high $2.85 Avg. volume 164,594
50-day MA $2.57 Dividend yield N/A
200-day MA $2.76 Market Cap 109.38M

Harvard Bioscience, Inc. (HBIO) Company Bio


Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science research. The company was founded in 1901 and is based in Holliston, Massachusetts.

HBIO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$2.85$1.79-35%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Harvard Bioscience Inc. To summarize, we found that Harvard Bioscience Inc ranked in the 38th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 34.5%. The most interesting components of our discounted cash flow analysis for Harvard Bioscience Inc ended up being:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 64. Its equity weight surpasses that of just 17.02% of free cash flow generating stocks in the Healthcare sector.
  • Harvard Bioscience Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.54. This coverage rate is greater than that of merely 19.05% of stocks we're observing for the purpose of forecasting via discounted cash flows.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-36%
1%-35%
2%-35%
3%-34%
4%-34%
5%-33%

BDX, SGRY, TARO, USPH, and ITGR can be thought of as valuation peers to HBIO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


HBIO Latest News Stream


Event/TimeNews Detail
Loading, please wait...

HBIO Latest Social Stream


Loading social stream, please wait...

View Full HBIO Social Stream

Latest HBIO News From Around the Web

Below are the latest news stories about Harvard Bioscience Inc that investors may wish to consider to help them evaluate HBIO as an investment opportunity.

Harvard Bioscience, Inc. Issues Letter to Shareholders

Jim Green, Chairman, President & Chief Executive Officer of Harvard Bioscience, Inc. (HBIO) (the “Company” or “Harvard Bioscience”), today issued a letter to shareholders updating them on the Company’s execution against the key strategic actions committed to in September 2019 to position Harvard Bioscience for long-term profitable growth. In addition, we expect to complete the streamlining of our UK operation next quarter.

Yahoo | May 26, 2020

Harvard Bioscience (HBIO) Reports Q1 Loss, Lags Revenue Estimates

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -125.00% and -15.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research | May 5, 2020

Harvard Bioscience Announces First Quarter 2020 Financial Results

HOLLISTON, Mass., May 05, 2020 -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the three months ended March 31, 2020. The.

Yahoo | May 5, 2020

Is There An Opportunity With Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 50% Undervaluation?

Does the May share price for Harvard Bioscience, Inc. (NASDAQ:HBIO) reflect what it's really worth? Today, we will...

Yahoo | May 1, 2020

Harvard Bioscience (HBIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research | April 28, 2020

Read More 'HBIO' Stories Here

HBIO Price Returns

1-mo 12.65%
3-mo 2.89%
6-mo 0.00%
1-year 43.22%
3-year 14.00%
5-year -46.83%
YTD -6.56%
2019 -4.09%
2018 -3.64%
2017 8.20%
2016 -12.10%
2015 -38.80%

Continue Researching HBIO

Want to see what other sources are saying about Harvard Bioscience Inc's financials and stock price? Try the links below:

Harvard Bioscience Inc (HBIO) Stock Price | Nasdaq
Harvard Bioscience Inc (HBIO) Stock Quote, History and News - Yahoo Finance
Harvard Bioscience Inc (HBIO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.3791 seconds.